Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression
Biotechnology Journal · 2026
DOI: 10.1002/biot.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2026. Verfasst von Jason Vitko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA. Hauptthemen laut MEDLINE: DNA Transposable Elements, Genetic Vectors, Antibodies, Monoclonal. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
The use of transposon‐based technologies in cell line development has gained significant traction over the past decade. This study investigates the piggyBac transposon system combined with bicistronic vectors for monoclonal antibody expression, helping address the complex demands of multi‐specific antibody formats that require multiple cistrons. We systematically evaluated bicistronic vector modifications within the piggyBac framework, including promoter sequences, reporter placements, and cassette configurations, and compared performance to piggyBac /single‐gene vector co‐transfection methods. Our findings demonstrate that double human CMV promoter configurations driving both heavy and light chain genes significantly enhanced pool productivity (2 to 2.5‐fold) and reporter expression compared to separate promoter designs. Among tested cassette arrangements, the Light chain‐GS‐Heavy chain configuration yielded optimal productivity (1.5 to 6‐fold) and superior heavy chain/light chain RNA transcript ratios (1.4 to 3.8‐fold and 1.3 to 6.1‐fold, respectively). While unfed batch conditions showed comparable productivities between optimized piggyBac /bicistronic and piggyBac /single‐gene systems, the bicistronic approach exhibited superior productivity performance under fed‐batch conditions (1.5‐fold), with the resulting clones demonstrating significantly high productivity (top clone 9.6 g/L). This represents the first reported use of LC‐selection marker‐HC topology for monoclonal antibody expression, establishing a foundation for improved therapeutic biologic production through multicistronic vector systems combined with the piggyBac transposon strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.
ORCID-Profile: Jason Vitko, Thomas King, Efecan Aral, Steven McLellan, Hope Divello, Tiffany McLamarrah
Förderung
- Sanofi
Zitieren
APA
Vitko, J., King, T., Aral, E., McLellan, S., Divello, H., Maimouni, S., McLamarrah, T., Tedstone, J., Cairns, V., DeMaria, C., & Scarcelli, J. J. (2026). Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression. Biotechnology Journal. https://doi.org/10.1002/biot.70296
Vancouver
Vitko J, King T, Aral E, McLellan S, Divello H, Maimouni S, et al. Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression. Biotechnology Journal. 2026. doi:10.1002/biot.70296
BibTeX
@article{Vitko2026,
author = {Vitko, Jason and King, Thomas and Aral, Efecan and McLellan, Steven and Divello, Hope and Maimouni, Sara and McLamarrah, Tiffany and Tedstone, Jennifer and Cairns, Victor and DeMaria, Christine and Scarcelli, John J},
title = {Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression},
journal = {Biotechnology Journal},
year = {2026},
doi = {10.1002/biot.70296}
}
EUVIMED